Phillip McGhee, MD
Family Medicine · Oklahoma City, OKNPI 1114347747
Payments from drug & device makers
Across 179 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$335
- Johnson & Johnson$282
- Lilly USA, LLC$279
- Boehringer Ingelheim$258
- Novo Nordisk$227
- Amgen$204
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,691100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $335 |
| Johnson & Johnson | 6 | $282 |
| Lilly USA, LLC | 22 | $279 |
| Boehringer Ingelheim | 22 | $258 |
| Novo Nordisk | 19 | $227 |
| Amgen | 7 | $204 |
| AstraZeneca | 10 | $187 |
| GSK | 8 | $180 |
| Merck | 19 | $171 |
| Shire North American Group Inc | 10 | $112 |
| Amarin Pharma, Inc. | 7 | $102 |
| Astellas Pharma US Inc | 4 | $58 |
| AbbVie | 4 | $57 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $25 |
| Gilead | 1 | $20 |
| Abbott | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$119
- AIMOVIG$115
- TRELEGY ELLIPTA$108
- INVOKANA$102
How this compares
$2,691 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $105,382 |
| JardianceEmpagliflozin | 63 | $79,810 |
| OzempicSemaglutide | 41 | $68,637 |
| TrulicityDulaglutide | 28 | $44,078 |
| EliquisApixaban | 40 | $44,007 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $32,658 |
| JanuviaSitagliptin Phosphate | 28 | $28,168 |
| ProliaDenosumab | 15 | $26,422 |
| Sumatriptan Succinate | 34 | $19,456 |
| XareltoRivaroxaban | 26 | $19,144 |
| MyrbetriqMirabegron | 21 | $14,343 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $14,044 |
| Atorvastatin Calcium | 510 | $5,555 |
| Omeprazole | 169 | $4,291 |
| Gabapentin | 234 | $4,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $279 | $149,460110 claims |
| Boehringer IngelheimJardiance | $258 | $79,81063 claims |
| Novo NordiskOzempic | $227 | $68,63741 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $180 | $46,70279 claims |
| PfizerEliquis | $335 | $44,00740 claims |
| MerckJanuvia | $171 | $28,16828 claims |
| AmgenProlia | $204 | $26,42215 claims |
| Johnson & JohnsonXarelto | $282 | $19,14426 claims |
| Astellas Pharma US IncMyrbetriq | $58 | $14,34321 claims |
| AbbVieSynthroid | $57 | $1,77528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.